Compounds > sb 216763
Page last updated: 2024-09-05

sb 216763 and Lymphoma, Non-Hodgkin

sb 216763 has been researched along with Lymphoma, Non-Hodgkin in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Coats, JT; Sutherland, C; Tauro, S1

Other Studies

1 other study(ies) available for sb 216763 and Lymphoma, Non-Hodgkin

ArticleYear
Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition.
    Cell communication and signaling : CCS, 2023, 06-14, Volume: 21, Issue:1

    Topics: beta Catenin; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lymphoma, Non-Hodgkin

2023